1,2
Allergan surveyed* 17,929 consumers and 360 medical aesthetics professionals in 12 countries around the world to establish both the consumer and healthcare professional (HCP) perception of trust, and its role in the medical aesthetics industry.
International survey results
Why is trust important
TO PEOPLE?
1,2
n=17,929
regularly research facial skincare products
n=17,929
of consumers say looking good is very
important to them
n=360
to feel confident in their product choice
n=360
to feel they are
doing the best for
their patients
n=360
to believe the product is of
high quality
n=360
to feel they will consistently achieve the best results
Among HCPs, trust in medical aesthetics brands allows:
Trust is an important aspect of medical aesthetics treatments
1,2
of HCPs say that trust is very important
to them when considering an injectable
toxin** as a treatment option
n=360
n=13,485
n=13,962
n=13,413
n=13,186
Dermabrasion
Chemical peels
Facial threads
Injectable toxins**
For consumers, the importance of trust in injectable toxins** ranks favourably compared to other facial aesthetics treatments
lack of potential side effects or complications
n=360
positive results
n=360
longevity of
results
n=360
n=4,776
When selecting their preferred medical aesthetics brands, HCPs are influenced by:
of people who may consider facial injections in the future say that a brand being supported by positive clinical studies and evidence would be one of the top
three most important factors in
their decision making
1,2
The role of clinical
evidence in trust
the doctor answering any questions that they have
n=5,377
a knowledgeable doctor
n=5,377
information provided about potential side effects and complications
n=5,377
1
n=360
availability of
long term data
n=360
number of
clinical studies available
n=360
manufactured by
a well-known,
trusted company
For those considering future facial aesthetics treatments, among the most important factors for a consultation include:
Which factors contribute the most to trust in medical aesthetics?
2
The most important factors contributing to trust in medical aesthetics brands for HCPs are:
It is Allergan’s ambition to educate consumers and healthcare professionals (HCPs) about the importance of trust within the medical aesthetics industry. The Importance of Trust in Beauty survey hopes to emphasise the importance of education when making aesthetics choices.
The focus for patients is on making sure they do their research in order
to find a qualified medical aesthetics practitioner who will be focused
on ensuring a good consultation and treatment outcomes. For HCPs, the survey hopes to emphasise how a good consultation results in a trusted relationship between the HCP and their patient, as well as better treatment outcomes.
References
1. INT/0162/2018 Allergan Unpublished Data, The Importance of Trust in Beauty Survey – Consumer Data, March 2018.
2. INT/0162/2018a Allergan Unpublished Data, The Importance of Trust in Beauty Survey – Healthcare Professional Data,
March 2018.
Date of preparation: April 2018 | Job number: INT/0149/2018h
Produced and funded by
* The consumer and healthcare professional (HCP) comparison survey was commissioned by Allergan and conducted
by Kantar Health and Kantar Millward Brown in January – March 2018 via online interviews. For consumers, the report captures the attitudes of 17,929 male and female respondents aged 20 – 65 from twelve countries – UK, France, Germany, Italy, Spain, Brazil, Saudi Arabia, Turkey, Russia, Australia, Canada and China. These respondents form a sub-sample of a wider dataset of 22,652 members of the general public, and they were screened in to complete the study based on their attitudes towards their face and body (as well as age and occupational exclusion criteria). These figures provided a representative sample across each of the countries. These survey data are part of a wider ongoing piece of primary market research being conducted in a further 5 markets (India, South Korea, Taiwan, Thailand, UAE).
For HCPs, the report captures the attitudes of 360 practitioners including plastic and cosmetic surgeons, dermatologists, and nurse practitioners in twelve countries: UK, France, Germany, Italy, Spain, Turkey, Brazil, Saudi Arabia, Russia, Australia, Canada and China; 30 online interviews were conducted per country. HCPs who participated in the survey were regularly treating patients using botulinum toxin and/or dermal fillers; and none were affiliated with any pharmaceutical company.
Kantar Health and Kantar Millward Brown, part of the Kantar group, are accredited international market research agencies that specialise in conducting market research. As members of BHBIA, ESOMAR and Market Research Society, Kantar Health and Kantar Millward Brown stringently adhere to these professional codes when conducting international research.
** Toxin refers to botulinum toxin approved for facial use.
